Drs Ursula A. Matulonis and Gini F. Fleming discuss the state of endometrial cancer, the role of immunotherapy, and priorities for research in this field.

If you have recurrent endometrial cancer, your doctor will talk to you about your treatment options, including radiation, chemotherapy, immunotherapy, or sometimes surgery. (Photo Credit ...

Dual checkpoint inhibitors led to longer overall survival in patients with high-risk endometrial cancer who displayed ...

GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherapy option for first-line ...

We know that combining with immunotherapy is critical ... about whether we should be rebiopsying our patients with endometrial cancer at the time of progression to see if the molecular profiling ...

Black patients with metastatic triple-negative breast cancer received immunotherapy less frequently than patients of other ...

The result comes after GSK reported that Jemperli (dostarlimab) plus chemo hit the mark in the RUBY trial in primary advanced or recurrent endometrial cancer, becoming the first immunotherapy to ...

Endometrial cancer is one of the most common gynaecological cancers in high-income countries and, for many years, has been ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad ...

"P-Sam is an exciting new ADC targeting B7-H4, which is expressed in approximately 73% of endometrial ... cancer whose disease has progressed following platinum chemotherapy and immunotherapy.